Stop me if you’ve heard this one: AstraZeneca is having vaccine issues

Remember when I said “we’ll see if anything else happens” in last week’s article on AstraZeneca’s issues? Well, I accept full responsibility for manifesting the chaos that happened earlier this week and I promise I won’t tempt fate again this time around. If you’re confused, as I certainly was, here’s just what the hell happened.

On Monday, AstraZeneca released results from their Phase 3 trials in the United States, and they looked good: 79% efficacy against symptomatic disease, 100% efficacy against hospitalizations and deaths. This was certainly a welcome result for the company which is continuing to grapple with fallout from rare cases of blood clots that have been reported in some people after they got the vaccine, and gears started to turn to get EUA approval in the United States. (Even though, again, the U.S. just promised most of their supply to Canada and Mexico. Everyone wants FDA clout, I guess.)

But on Tuesday, officials started to question the results. The results released on Monday had looked better than more recent results released elsewhere, one of which showed an overall efficacy of around 60%. Also, as Dr. Eric Topol pointed out, the data were fairly incomplete:

Independent reviewers from the data and safety monitoring board sent “a harsh note” to AstraZeneca, according to Anthony Fauci, and sure enough, it soon became clear that AstraZeneca had released outdated (better) numbers instead of the real results from the trial, obfuscating how efficacious the vaccine actually was in the U.S. trial. 

After all this, on Wednesday morning, AstraZeneca released the updated overall efficacy number: 76%. All that drama over docking three percentage points. (Though they did also complete the dataset, thus satisfying Dr. Topol and saving them more of his very pointed tweets. Thank you Dr. Topol.) 

Dr. Ashish Jha sums it up pretty well:

But Roxanne Khamsi sums it up even better:

We’ll see if anything el—nope, I promised I wouldn’t.

Related posts

  • The future of COVID-19 vaccines needs more data
    On Thursday, the FDA’s Vaccines and Related Biological Products Advisory Committee (or VRBPAC) met to discuss the future of COVID-19 vaccines. While the committee readily agreed that our current, Omicron-specific shots are working well and should be used more broadly, it had a hard time answering other questions about future vaccine regimens—largely due to a lack of good data.
  • Sources and updates, December 18
    Sources and updates for the week of December 18 include at-home test orders, lives saved by vaccines, state-level wastewater surveillance, and more.
  • Sources and updates, December 11
    Sources and updates for the week of December 11 include America’s Health Rankings, bivalent boosters for kids, and more.
  • Sources and updates, December 4
    Sources and updates for the week of December 4 include new CDC grants to support public health infrastructure, breakthrough COVID-19 deaths, monoclonal antibodies, and more.

One thought on “Stop me if you’ve heard this one: AstraZeneca is having vaccine issues

Leave a Reply